GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Nanogen Gains Access to Schizophrenia Markers

  • Nanogen acquired rights to genetic markers related to schizophrenia and responses to antipsychotic therapies from the Co-operative Research Centre for Diagnostics and Queensland University of Technology in Australia.

    Nanogen plans to utilize the markers to create diagnostic tests. Some of these markers may also help predict adverse drug reactions and therefore guide therapeutic decision-making.

    "Due to its complexity—schizophrenia, like many mental disorders, is believed to be caused by mutations in multiple genes— development of effective diagnostics and treatments is likely to require multiplexed analytic methods capable of examining multiple genes simultaneously," remarks David Ludvigson, Nanogen's president and COO.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »